Florida is currently home to 3774 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Systemic Hypothermia in Acute Cervical Spinal Cord Injury
Recruiting
This study is a prospective multi-center trial designed to determine the safety profile and efficacy of modest (33ºC) intravascular hypothermia following acute cervical (C1 to C8) Spinal Cord Injury (SCI).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/16/2025
Locations: Jackson Memorial Hospital, Miami, Florida
Conditions: Spinal Cord Injury, Acute
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Recruiting
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Research Site, Fort Myers, Florida
Conditions: Endometrial Cancer
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Recruiting
Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night. People with NT2 may fall asleep suddenly, have trouble staying awake during the day, or may not be able to sleep well at night. They may have difficulty thinking clearly, paying attention, or remembering things, during the day. These symptoms can make daily activities like driving, working, or caring for their families chall... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/15/2025
Locations: Takeda Site 13, Brandon, Florida
Conditions: Narcolepsy Type 2
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Recruiting
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Innovative Research of West Florida, Clearwater, Florida
Conditions: Overweight, Type 2 Diabetes, Obesity
Sweet Corn and Carotenoids
Recruiting
This study will assess the effect of daily yellow and white sweet corn intake on serum lutein and zeaxanthin concentrations. Skin carotenoid levels using the Veggie Meter will be assessed, and gastrointestinal symptoms and changes in fecal microbiota during a 4-week intervention period will be monitored.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/15/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Carotenoids
Pulsed Electromagnetic Field Treatment With Dementia Patients
Recruiting
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end point is the The Alzheimer's Disease Assessment Scale-Cognitive Subscale. Participants will be followed-up for 9 months post-treatment.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
05/15/2025
Locations: University of Miami, Boca Raton, Florida
Conditions: Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
Recruiting
This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with mild, moderate, and severe hepatic impairment compared with participants with normal hepatic function.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/15/2025
Locations: Research Site, Orlando, Florida
Conditions: Hepatic Impairment
Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Recruiting
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Clermont Oncology Center, Clermont, Florida
Conditions: Non-small Cell Lung Cancer
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/15/2025
Locations: AMR-Miami, Coral Gables, Florida
Conditions: Diabetic Peripheral Neuropathic Pain
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Recruiting
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the format... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Holy Cross Hospital, Fort Lauderdale, Florida
Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian High Grade Endometrioid Adenocarcinoma
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy.
Recruiting
The goal of this observational study is to follow patients being treated with the FDA approved drug AGAMREE® in male patients 2 years of age or older with Duchenne's Muscular Dystrophy for long term safety and quality of life.
Gender:
MALE
Ages:
2 years and above
Trial Updated:
05/15/2025
Locations: University of Florida Clinical and Translational Science Institue, Gainesville, Florida
Conditions: Duchenne Muscular Dystrophy
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
Recruiting
The purpose of this study is to explore the clinical utility of routinely measuring thymidine kinase activity (TKa) in HR+ metastatic breast cancer patients receiving treatment with any approved endocrine therapy either alone or in combination with any approved CDK4/6 inhibitor.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer